

PT572 – The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics Could Prevent Nuclear War, with Howard Kornfeld, MD
5 snips Dec 10, 2024
Howard Kornfeld, a renowned pain medicine expert and addiction specialist, discusses the promise of buprenorphine as a treatment for both addiction and chronic pain, comparing it to MDMA. He shares insights on the historical context and potential of ketamine, while also warning about its risks. Kornfeld provocatively connects psychedelics to nuclear disarmament, citing their ability to change minds and promote peace. The conversation emphasizes the need for innovative research and responsible use of psychedelics in addressing global challenges.
AI Snips
Chapters
Transcript
Episode notes
Buprenorphine and MDMA Parallels
- Buprenorphine's FDA approval process offers a potential roadmap for MDMA.
- Both are controlled substances proposed for life-threatening conditions.
Expanded Access for MDMA
- Explore expanded access programs for MDMA under FDA study umbrella.
- This would allow more veterans to receive MDMA treatment.
Rethinking Psychedelic Study Design
- Double-blind studies may not be suitable for psychedelic research.
- Explore alternative study designs like matched controls.